Cited by 594Cell death mechanisms and regulationMitochondrial Function and PathologyPARP inhibition in cancer therapy

Parthanatos: mitochondrial‐linked mechanisms and therapeutic opportunities

Open access
Fatokun, Amos A, Dawson, Valina L, Dawson, Ted M·2014·British Journal of Pharmacology

Abstract

Cells die by a variety of mechanisms. Terminally differentiated cells such as neurones die in a variety of disorders, in part, via parthanatos, a process dependent on the activity of poly (ADP‐ribose)‐polymerase (PARP). Parthanatos does not require the mediation of caspases for its execution, but is clearly mechanistically dependent on the nuclear translocation of the mitochondrial‐associated apoptosis‐inducing factor (AIF). The nuclear translocation of this otherwise beneficial mitochondrial protein, occasioned by poly (ADP‐ribose) (PAR) produced through PARP overactivation, causes large‐scale DNA fragmentation and chromatin condensation, leading to cell death. This review describes the multistep course of parthanatos and its dependence on PAR signalling and nuclear AIF translocation. The review also discusses potential targets in the parthanatos cascade as promising avenues for the development of novel, disease‐modifying, therapeutic agents. Linked Articles: This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue‐8

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.12416

Cites

184 of 184 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Parthanatos occurs not only as a consequence of severe/prolonged alkylating DNA damage, but also in response to oxidative stress, hypoxia, hypoglycemia, or inflammatory cues.

    “parthanatos appears to occur not only as a consequence of severe/prolonged alkylating DNA damage, but also in response to oxidative stress, hypoxia, hypoglycemia, or inflammatory cues [656–658].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fatokun, A. A., Dawson, V. L., & Dawson, T. M.
Affiliations
  • University of Nottingham (GB)
  • Johns Hopkins University (US)
Corresponding author
  • Fatokun, Amos A
  • Dawson, Ted M
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2014-03-28
Volume
171
Issue
8
Pages
2000-2016
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2117049355
Cited by
594
References
184
Citations by year
2026: 44 · 2025: 57 · 2024: 47 · 2023: 67 · 2022: 67 · 2021: 56 · 2020: 68 · 2019: 46 · 2018: 42 · 2017: 37 · 2016: 37 · 2015: 14 · 2014: 12
FWCI
1.96
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Drug Abuse (P50DA000266, DA000266)
  • National Institute of Neurological Disorders and Stroke (NS 38377, NS067525, R37NS067525, P50NS038377, R01NS067525)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
parthanatos, apoptosis, poly(ADP-ribose) polymerase, apoptosis-inducing factor, poly(ADP-ribose), DNA fragmentation, chromatin condensation, neurodegeneration, disease-modifying therapy
MeSH terms
Poly (ADP-Ribose) Polymerase-1, Animals, Cell Survival, Glycoside Hydrolases, Humans, Mitochondria, Models, Biological, Poly Adenosine Diphosphate Ribose, Poly(ADP-ribose) Polymerases, Cell Death, Neurodegenerative Diseases, Active Transport, Cell Nucleus, Apoptosis Inducing Factor, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review